{
    "Symbol": "OGN",
    "AssetType": "Common Stock",
    "Name": "Organon & Co",
    "Description": "Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.",
    "CIK": "1821825",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "30 HUDSON STREET, FL 33, JERSEY CITY, NJ, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2022-12-31",
    "MarketCapitalization": "6282177000",
    "EBITDA": "1928000000",
    "PERatio": "6.77",
    "PEGRatio": "None",
    "BookValue": "-3.507",
    "DividendPerShare": "1.12",
    "DividendYield": "0.0455",
    "EPS": "3.64",
    "RevenuePerShareTTM": "24.3",
    "ProfitMargin": "0.148",
    "OperatingMarginTTM": "0.278",
    "ReturnOnAssetsTTM": "0.0991",
    "ReturnOnEquityTTM": "0",
    "RevenueTTM": "6174000000",
    "GrossProfitTTM": "3889000000",
    "DilutedEPSTTM": "3.64",
    "QuarterlyEarningsGrowthYOY": "-0.469",
    "QuarterlyRevenueGrowthYOY": "-0.074",
    "AnalystTargetPrice": "31.89",
    "TrailingPE": "6.77",
    "ForwardPE": "5.03",
    "PriceToSalesRatioTTM": "1.143",
    "PriceToBookRatio": "1.843",
    "EVToRevenue": "2.397",
    "EVToEBITDA": "8.06",
    "Beta": "None",
    "52WeekHigh": "37.89",
    "52WeekLow": "20.96",
    "50DayMovingAverage": "23.65",
    "200DayMovingAverage": "26.98",
    "SharesOutstanding": "254383000",
    "DividendDate": "2023-03-16",
    "ExDividendDate": "2023-02-24"
}